id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2013-D-1630-0010,FDA,FDA-2013-D-1630,"Guidance on Qualification of Biomarker—Galactomannan in Studies
of Treatments of Invasive Aspergillosis; Guidance for Industry",Other,Guidance,2015-11-13T05:00:00Z,2015,11,2015-11-13T05:00:00Z,,2024-11-07T23:35:31Z,,1,0,0900006481d40a1d
FDA-2013-D-1630-0009,FDA,FDA-2013-D-1630,"Guidance on Qualification of Biomarker—Galactomannan in Studies
of Treatments of Invasive Aspergillosis; Guidance for Industry; Availability",Notice,Notice of Availability,2015-11-13T05:00:00Z,2015,11,2015-11-13T05:00:00Z,2016-01-13T04:59:59Z,2016-01-13T22:00:55Z,2015-28804,0,0,0900006481d3f8ea